Clinical trials: Breast Cancer, Metastatic Breast Cancer
ER-positive and HER2-negative Metastatic or Locally Advanced Breast Cancer, a Germline or Somatic BRCA Mutation, or a Deleterious Alteration of Other Genes Involved in Homologous Recombination Repair (HRR) or in MSI Status
Durvalumab, With Olaparib and Fulvestrant in Advanced ER+, HER2- Breast Cancer Patients.
This study evaluates the efficacy of the combination of olaparib, durvalumab, and fulvestrant for the treatment of patients with ER-positive, HER2-negative, locally advanced or metastatic breast cancer with BRCA gene alterations…
- Trial name
- DOLAF (NCT04053322)
- Testing
- Durvalumab, Olaparib, Fulvestrant
- Where
- 2 sites in France
- Volunteers
- 172 people
- Sponsor
- UNICANCER
Breast Cancer Metastatic
A Study Evaluating The PF-03084014 In Combination With Docetaxel In Patients With Advanced Breast Cancer
This study is aimed to determine the tolerability of the PF-03084014 plus docetaxel combination in patients with advanced breast cancer. Preliminary information about the efficacy of the combination will also be collected.
- Trial name
- NCT01876251
- Testing
- PF-03084014, Docetaxel
- Where
- 16 sites in United States, Belgium and 2 more
- Volunteers
- 30 people
- Sponsor
- Pfizer
Breast Cancer
Clinical Trial of Evaluating TQB3912 Tablets Combined With Fulvestrant Injection±TQB3616 Capsules for Locally Advanced or Metastatic Hormone Receptor(HR)-Positive and Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
This trial was designed to evaluate the maximum tolerated dose (MTD) and phase II recommended dose (RP2D) in subjects with TQB3912 tablets combined with fulvestrant injection and TQB3616 capsules for locally advanced or…
- Trial name
- NCT06851442
- Testing
- TQB3912 tablets in combination with fulvestrant injection± TQB3616 capsules
- Where
- 17 sites in China
- Volunteers
- 8 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Breast Cancer Metastatic, Hormone Receptor Positive Malignant Neoplasm of Breast
Rogaratinib, Palbociclib y Fulvestrant in Patients With Breast Cancer.
This study is an open, multicenter, prospective phase I dose escalation clinical trial followed by an expansion cohort. The aim of this study is to asses the Recommended Phase 2 Dose (R2PD) and the safety profile, among other…
- Trial name
- ROGABREAST (NCT04483505)
- Testing
- Combination, Rogaratinib + palbociclib + fulvestrant
- Where
- 8 sites in Spain
- Volunteers
- 9 people
- Sponsor
- Fundacion CRIS de Investigación para Vencer el Cáncer
Breast Cancer
BMS-247550 in Treating Women With Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of BMS-247550 in treating women who have stage IV or…
- Trial name
- NCT00020904
- Testing
- ixabepilone
- Where
- 2 sites in United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Cancer
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
This study was a multi-center, randomized, double-blind, placebo controlled Phase III study to determine the efficacy and safety of treatment with buparlisib plus fulvestrant versus fulvestrant plus placebo in postmenopausal…
- Trial name
- BELLE-2 (NCT01610284)
- Testing
- Fulvestrant, BKM120
- Where
- 268 sites in United States, Argentina and 27 more
- Volunteers
- 1,147 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer, Metastatic Breast Cancer
89Zr-DFO*-Trastuzumab PET in Patients With Gastric or Breast Cancer - a Pilot Study
The goal of this clinical trial is to test a new PET tracer in patients with HER2-positive breast or gastric cancer. This tracer is made of radioactively labeled trastuzumab, and can show where HER2 is present in the body using a…
- Conditions
- Breast Cancer, Metastatic Breast Cancer, HER2-positive Breast Cancer, Gastric Cancer
- Trial name
- HER Image (NCT05955833)
- Testing
- 89Zr-DFO*-trastuzumab PET scan
- Where
- Netherlands
- Volunteers
- 6 people
- Sponsor
- Amsterdam UMC, location VUmc
Advanced Breast Cancer
Phase II Dasatinib Study in Advanced Breast Cancer
The purpose of this study is to find out if dasatinib will safely reduce the size or spread of your tumor.
- Trial name
- NCT00546104
- Testing
- Dasatinib
- Where
- 3 sites in United States
- Volunteers
- 31 people
- Sponsor
- Duke University
TNBC - Triple-Negative Breast Cancer, Breast Cancer
Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC)
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of trilaciclib versus placebo administered prior to gemcitabine and carboplatin in patients receiving first- or…
- Trial name
- PRESERVE 2 (NCT04799249)
- Testing
- Trilaciclib, Gemcitabine, Carboplatin
- Where
- 71 sites in United States, Australia and 9 more
- Volunteers
- 194 people
- Sponsor
- G1 Therapeutics, Inc.
Breast Cancer
Management of Metastatic Breast Cancer in Frail Patients
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of gemcitabine in treating elderly women who have…
- Trial name
- NCT00005614
- Testing
- Gemcitabine hydrochloride
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Breast Cancer
Lapatinib in Combination With Trastuzumab in Patients With HER2-Positive, Metastatic Breast Cancer
In this research study we are studying the effects of the combination of lapatinib plus Herceptin in subjects with breast cancer that has spread outside of the breast.
- Trial name
- NCT00470704
- Testing
- Lapatinib, Herceptin
- Where
- 9 sites in United States
- Volunteers
- 87 people
- Sponsor
- Nancy Lin, MD
Breast Cancer
Trastuzumab-deruxtecan in Patients With Triple-negative Metastatic HER2-Low Breast Cancer: Real-world Experience in Brazil
A national, multicenter, retrospective, observational study (Real-World Evidence-RWE) aimed to assess the efficacy of Trastuzumab-deruxtecan (T-DXd) in patients with triple-negative (RE<10%) metastatic HER2-Low breast cancer.
- Trial name
- NCT06231693
- Testing
- Trastuzumab deruxtecan
- Where
- 2 sites in Brazil
- Volunteers
- 2 people
- Sponsor
- AstraZeneca
Breast Cancer, Cognitive/Functional Effects
Study of Symptoms Caused by Cancer and Cancer Therapy in Patients With Invasive Breast, Lung, Prostate, or Colorectal Cancer
RATIONALE: Questionnaires that assess symptoms caused by cancer and cancer therapy may help improve the ability to plan treatment for patients with invasive cancer to help them live longer and more comfortably.
- Conditions
- Breast Cancer, Cognitive/Functional Effects, Colorectal Cancer, Lung Cancer
- Trial name
- NCT00303914
- Testing
- assessment of therapy complications, cognitive assessment, psychosocial assessment and care
- Where
- 32 sites in United States
- Volunteers
- 2,310 people
- Sponsor
- Eastern Cooperative Oncology Group
Recurrent Breast Cancer, Stage IV Breast Cancer
PS-341 in Treating Women With Metastatic Breast Cancer
PS-341 may stop the growth of tumor cells by blocking the enzymes necessary for cancer cell growth. Phase II trial to study the effectiveness of PS-341 in treating women who have metastatic breast cancer
- Trial name
- NCT00025584
- Testing
- bortezomib, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Breast Cancer
A Study of Abemaciclib (LY2835219) in Participants With HR+, HER2- Advanced Breast Cancer
The reason for this study is to see if the drug abemaciclib in combination with nonsteroidal aromatase inhibitors (anastrozole or letrozole) is effective in participants with Hormone Receptor Positive (HR+), Human Epidermal…
- Trial name
- proMONARCH (NCT03988114)
- Testing
- Abemaciclib, Nonsteroidal Aromatase Inhibitor (NSAI)
- Where
- 119 sites in United States, Argentina and 7 more
- Sponsor
- Eli Lilly and Company
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
Leuprolide and Goserelin for Ovarian Function Suppression in Pre- or Peri-menopausal Women With Breast Cancer, OFS Trial
This phase II trial compares leuprolide to goserelin for reducing estrogen production by the ovaries in pre- or peri-menopausal women with breast cancer. Estrogen can cause the growth of breast cancer cells.
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8
- Trial name
- NCT07158021
- Testing
- Biospecimen Collection, Electronic Health Record Review, Goserelin
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- University of Michigan Rogel Cancer Center
Advanced Solid Tumor, Metastatic Breast Cancer
A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer
This is a multicenter, open label, nonrandomized, sequential dose escalation/dose ranging, multiple dose study designed to evaluate the safety, toxicity, and PK as well as preliminary efficacy of BTX-A51 alone and in combination…
- Trial name
- NCT04872166
- Testing
- BTX-A51
- Where
- 6 sites in United States
- Volunteers
- 112 people
- Sponsor
- Edgewood Oncology Inc.
Breast Cancer
A Study of Bevacizumab (Avastin) in Women With HER2 Negative Metastatic Breast Cancer
This study will evaluate the efficacy and safety of 2 doses of Avastin in combination with docetaxel, versus docetaxel plus placebo, in patients with metastatic HER2 negative breast cancer who are candidates for taxane-based…
- Trial name
- NCT00333775
- Testing
- Docetaxel, Bevacizumab
- Where
- 114 sites in Australia, Austria and 22 more
- Volunteers
- 736 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer, Metastatic Breast Cancer
Mapping the Enhanced Landscape of Advanced Breast Cancer fOr DYnamic Treatment Approaches
MELODY is a prospective, single-arm phase II study introducing routine liquid-biopsy next-generation sequencing for patients with advanced or unresectable breast cancer in Ireland.
- Conditions
- Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast Cancer (LABC)
- Trial name
- MELODY (NCT07893730)
- Testing
- Liquid biopsy next generation sequencing
- Volunteers
- 50 people
- Sponsor
- University College Cork
Advanced Solid Tumors
Study of Continuous OSI-906 Dosing
Multicenter, open-label, phase 1, cohort dose escalation study to determine the Maximum Tolerated Dose (MTD) on both Once Daily (QD) and Twice Daily (BID) schedules.
- Trial name
- NCT00514007
- Testing
- OSI-906
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 95 people
- Sponsor
- Astellas Pharma Inc
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.